Investor Presentaiton slide image

Investor Presentaiton

Strengthen Portfolio Best, early-stage translational portfolio from one integrated partner Enhancing our scientific capabilities with a focus on advanced modalities (incl. C&GT) and key therapeutic areas Continue to expand expertise around humanized models, CRADL™, antibody discovery, bioanalysis and advanced screening capabilities, microbial detection, process development, and next-generation sequencing ■ Selectively adding to portfolio via technology partnerships and our M&A roadmap to create even more compelling value for our clients Will also evaluate creative and new opportunities to partner with emerging biotech clients earlier in the R&D process, including our VC relationships and biohubs strategy Enable clients to advance their drugs to the clinic and commercial phase faster and more efficiently Charles River Laboratories (CRL) 18
View entire presentation